Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)
Sign Up to like & getrecommendations! Published in 2017 at "Haematologica"
DOI: 10.3324/haematol.2016.160408
Abstract: Over the past decade, the survival of patients with multiple myeloma (MM) has dramatically improved. This remarkable change is largely due to an increase in the anti-myeloma armamentarium, including next generation proteasome inhibitors (carfilzomib, ixazomib),… read more here.
Keywords: sustained response; venetoclax therapy; myeloma; response venetoclax ... See more keywords